Prostate Cancer

With a deluge of new drug treatments for advanced prostate cancer on the market, a care model emphasizing urologist and medical oncologist collaboration is needed, according to an article whose authors represent each specialty.

Risk classification changed in more than half of prostate cancers following assessment of cell cycle progression in tumors, according to a study reported at the Society of Urologic Oncology meeting in Bethesda, MD.

In this article, we briefly review the evaluation of patients with PPI and discuss the benefits and drawbacks of conservative, pharmacologic, injection, and surgical treatments.

The presence of a particular protein in biopsied prostate tissue substantially increases the likelihood that cancer will develop there, according to recent study.

The AUA recently joined with the American Association of Clinical Urologists and the Large Urology Group Practice Association in applauding the Physician’s Caucus of the United States Senate for their “commitment to preserving patient access to independent, integrated medical services.”

Men with hormone-sensitive metastatic prostate cancer who received docetaxel (Taxotere) given at the start of standard hormone therapy lived longer than patients who received hormone therapy alone, according to early study results that the lead investigator called “practice changing.”

British scientists have discovered that the presence of a specific protein can distinguish between indolent and aggressive prostate cancer.

When the pros and cons of prostate cancer treatment are spelled out using an online interactive program, more patients choose active surveillance over definitive treatment, according to researchers from Thomas Jefferson University in Philadelphia who developed the program.

The latest products and services from Mission Pharmacal, Eli Lilly, Richard Wolf Medical Instruments Corp., and Inspire on Purpose Publishing.

Men with prostate cancer who ate a low-fat diet and took fish oil supplements had lower levels of pro-inflammatory substances in their blood and a lower cell cycle progression score than men who ate a typical Western diet, UCLA researchers reported.

An investigational prostate cancer treatment slows the disease’s progression and may increase survival, especially among men whose cancer has metastasized to the bones, according to a recent analysis.

GenomeDx Biosciences has entered into contractual agreements for diagnostic laboratory testing as a participating provider that will expand insurance coverage for the company’s Decipher test for prostate cancer.

Men with prostate cancer treated with androgen deprivation therapy had significant improvement in strength and exercise capacity following a 10-week program of physical activity, education, and support, according to a study reported at the AUA annual meeting in San Diego.

Astellas Pharma US, Inc. and Medivation, Inc. have initiated a phase IV trial to evaluate the benefit of continued treatment with enzalutamide (Xtandi) beyond disease progression in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.

Men with advanced prostate cancer had similar survival with intermittent or continuous androgen deprivation therapy, pooled data from two randomized trials showed.

Data are lacking to recommend for or against the use of vitamins, minerals, and multivitamin supplements for the prevention of cancer and cardiovascular disease, according to a new U.S. Preventive Services Task Force draft recommendation statement.

No differences in body composition were found among metastatic castration-resistant prostate cancer patients taking abiraterone acetate (ZYTIGA), enzalutamide (Xtandi), or placebo who were treated as part of two clinical trials.

Prostate cancer has made its way into another set of Choosing Wisely recommendations, this time from the American Society of Clinical Oncology.

Fewer than 10% of patients are being told about the possibility of overdiagnosis and overtreatment as a result of screening for prostate and other cancers, according to findings from a recently published survey.

Men with short-ended chromosomes in the immune cells in their blood appear to be at increased risk for aggressive prostate cancer compared with men with long-ended chromosomes, according to findings from a recent study.

The latest products and services from SuperSonic Imagine, Auxilium Pharmaceuticals, VIVUS, the Centers for Medicare & Medicaid Services, Innovus Pharmaceuticals, Buffalo Filter, KRS Global Biotechnology, Demos Health, and Ethicon Endo-Surgery.

A phase III trial of enzalutamide (Xtandi) in chemotherapy-naïve patients with advanced prostate cancer has met both of its primary endpoints in an interim analysis, and the trial will be stopped early due to the drug’s benefit.

The publication of data in the New England Journal of Medicine (2013; 369:1629-37) showing an increase in intensity-modulated radiation therapy utilization among self-referring urologists has reignited the self-referral controversy.

Many physicians continue to administer the PSA test to even their oldest patients despite the fact that no medical organization recommends routine prostate cancer screening in men older than 75 years of age, according to recently published research.

Researchers at the Duke Cancer Institute in Durham, NC say they have developed a tool to forecast the potential survival of individual prostate cancer patients, enabling physicians to better assess whether to try additional rounds of treatment or seek clinical trials.

In this interview, Dr. Samir S. Taneja discusses the AUA's recommendations on the optimal method to perform a prostate biopsy and handle specimens as well as how to minimize infection and the role of imaging.

Primary androgen deprivation therapy for localized prostate cancer is associated with significantly better survival outcomes in a Japanese cohort compared with an American population, according to a recent study.

Single-fraction radiotherapy for bone metastases from prostate cancer is not widely used despite its comparable efficacy and lower cost in relation to multiple-fraction treatment, according to a recent study.

Data from a phase II study suggest that the potency of sipuleucel-T (Provenge) and immunologic prime-boost responses are maintained when the immunotherapy is administered concurrently or sequentially with abiraterone acetate (ZYTIGA) plus prednisone.

In its push to close the loophole on physician self-referral for prostate cancer treatment, the American Society for Radiation Oncology now has what some may call an unlikely ally.